MARKET

ENZ

ENZ

Enzo Biochem
NYSE

Real-time Quotes | Nasdaq Last Sale

3.540
-0.010
-0.28%
Opening 10:17 09/23 EDT
OPEN
3.540
PREV CLOSE
3.550
HIGH
3.660
LOW
3.500
VOLUME
39.16K
TURNOVER
--
52 WEEK HIGH
4.850
52 WEEK LOW
1.800
MARKET CAP
171.59M
P/E (TTM)
137.74
1D
5D
1M
3M
1Y
5Y
Capitol Series Trust Buys Cutera Inc, Genesco Inc, Enzo Biochem Inc, Sells Triumph Group Inc, ...
GuruFocus News · 6d ago
Those who invested in Enzo Biochem (NYSE:ENZ) a year ago are up 59%
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick...
Simply Wall St. · 09/12 13:35
ENZO BIOCHEM TO PRESENT AT THE H.C. WAINWRIGHT 23RD ANNUAL GLOBAL INVESTMENT CONFERENCE
NEW YORK, NY, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that management will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually...
GlobeNewswire · 09/02 20:05
VIEX Capital Advisors, LLC Buys Western Digital Corp, Xerox Holdings Corp, Zix Corp, Sells , ...
GuruFocus News · 08/23 23:38
Analyzing Enzo Biochem's Unusual Options Activity
Shares of Enzo Biochem (NYSE:ENZ) saw some unusual options activity on Wednesday. Following the unusual option alert, the stock price moved up to $3.19.
Benzinga · 08/11 15:54
FDA Expands EUA For Rapid Extraction On One COVID-19 Test System
Benzinga · 07/20 13:01
Enzo Biochem shares rise on FDA EUA expansion for SARS-CoV-2 test
Enzo Biochem (ENZ) shares climb more than 11% premarket after the company received an expansion of its FDA Emergency Use Authorization ((EUA)) for the rapid extraction method on its proprietary test system
Seekingalpha · 07/20 12:41
CAH,SAV,HCA and EDU among pre market gainers
NeuroBo Pharmaceuticals (NRBO) +36%.Immunome IMNM +29% rallies 31% after antibody cocktail neutralizes Delta variant in pre-clinical testingMediWound MDWD +19% announces positive topline results from Phase 3 pediatric ctudy (CIDS) of nexoBrid for eschar re...
Seekingalpha · 07/20 12:36
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ENZ. Analyze the recent business situations of Enzo Biochem through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ENZ stock price target is 5.50 with a high estimate of 5.50 and a low estimate of 5.50.
EPS
Institutional Holdings
Institutions: 112
Institutional Holdings: 26.72M
% Owned: 55.13%
Shares Outstanding: 48.47M
TypeInstitutionsShares
Increased
9
627.90K
New
16
3.32M
Decreased
32
5.74M
Sold Out
26
1.54M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
+0.49%
Healthcare Providers & Services
+0.80%
Key Executives
President/Treasurer
Barry Weiner
Chief Financial Officer
David Bench
Other
Kara Cannon
Other
Dieter Schapfel
Lead Director/Independent Director
Dov Perlysky
Director
Elazar Rabbani
Independent Director
Rebecca Fischer
Independent Director
Mary Tagliaferri
Independent Director
Ian Walters
No Data
  • All
  • Financials
  • Insiders
More
About ENZ
Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.

Webull offers kinds of Enzo Biochem, Inc. stock information, including NYSE:ENZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENZ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENZ stock methods without spending real money on the virtual paper trading platform.